Antiphospholipid antibodies and pregnancy

Area of Science:

• Obstetrics and Gynecology
• Immunology
• Reproductive Medicine

Background:

• Antiphospholipid antibodies, including lupus anticoagulants and anticardiolipin antibodies, are linked to adverse obstetric outcomes.
• Fetal death and recurrent spontaneous abortions are key obstetric criteria for antiphospholipid syndrome, affecting 15-20% of pregnancies.
• These antibodies significantly elevate the risk of pregnancy complications compared to controls.

Purpose of the Study:

• To summarize the association between antiphospholipid antibodies and obstetric complications.
• To review current treatment strategies and their effectiveness in pregnant women.
• To highlight the need for improved treatment protocols.

Main Methods:

• Literature review of studies on antiphospholipid antibodies and obstetric outcomes.
• Analysis of treatment efficacy for preventing recurrent pregnancy complications.
• Discussion of proposed mechanisms for antibody-induced fetal loss.

Main Results:

• Antiphospholipid antibodies are associated with a substantially increased risk of fetal death and recurrent spontaneous abortions.
• Current treatments, primarily heparin (unfractionated or low-molecular-weight) with or without low-dose aspirin, increase live birth rates from 0-40% to 70-80%.
• Despite treatment, a high frequency of maternal and/or fetal complications persists.

Conclusions:

• Antiphospholipid antibodies pose a significant risk to obstetric outcomes.
• While heparin-based therapies improve live birth rates, they are not fully effective.
• Further research is needed to optimize heparin treatment dosage, duration, and timing to minimize complications.